Random Effects Models
In order to assess the sensitivity of the results presented in Table 3 for the Primary Model with respect to the assumption that the outcomes are statistically independent across treatment episodes, we conducted sensitivity analyses under random effects models that allowed the outcomes to be statistically correlated across treatment episodes. We describe below the model specifications and analysis procedures.
Let Xji = 0 (failure) or 1 (success) denote the success/failure outcome for the i-th trial in the n-of-1 trial conducted for the j-th patient, where the between-patient index j=1,…,J denotes the patients, J denotes the total number of patients, and the within-patient index i=1, 2, 3, 4 denotes the four trials in the n-of-1 trial sequence for the j-th patient. Let Pji = P(Xji = 1) denote the success probability for the i-th trial in the j-th patient. Let us assume that the outcome Xji is determined from an underlying continuous propensity to succeed, Yji, as follows:
where the propensity to succeed, Yji, follows a standard normal distribution with mean zero and variance one,
and Tji is the threshold that determines the success/failure status Xji for the i-th trial in the j-th patient. It follows that the success probability Pji is given as follows:
where Φ is the cumulative distribution function for the standard normal distribution. Therefore,
For the Treatment Sequence A (MEME) in Figure 2 , the success probabilities for the Treatment Sequence A are given as follows in Table 1 :
the corresponding thresholds are given as follows:
(For the other three Treatment Sequences, the success probabilities and thresholds are permuted according to the specific Treatment Sequence.)
Let us assume further that the propensity vector (Yj1, Yj2, Yj3, Yj4) follows a random effect model,
where Aj denotes the random effect at the individual level, Bji denotes the residual variation for each trial within the same individual, with the following distributions: Under the primary model presented in Table 3 , and also shown in Table 2 as the column "Expected Proportion (Product of Probabilities)," the trial outcomes Xji's are assumed to be statistically independent across trials, i.e., the between-individual variance component τ 2 is assumed to be zero. Under this assumption, the joint probability for the outcome vector (Xj1, Xj2, Xj3, Xj4) is the product of the marginal probabilities, P(Xj1) × P(Xj2) × P(Xj3) × P(Xj4). For example, the joint probability for the outcome sequence SSSS (Xj1=1, Xj2=1, Xj3=1, Xj4=1) in Table 2 For the sensitivity analyses, we assume alternative values for the between-individual variance component τ 2 . In particular, we assume two scenarios, τ 2 = 0.20 and τ 2 = 0.50, with the results shown in Table 3 , footnote, and in Table 2 under the columns "Expected Proportion (20% Shared Variance)" and "Expected Proportion (50% Shared Variance)". The first scenario assumes a modest correlation in the treatment outcomes across treatment episodes, to capture the propensity for some patients to respond to treatments and other patients not to respond to treatments. The second scenario assumes a strong correlation across treatment episodes.
The joint probabilities reported in table 2 are derived using Monte Carlo integration. The algorithm is summarized below:
(a) We simulate a random value for A from the distribution (8), call it Aj.
(b) We derive the conditional probability for the outcome vector (Xj1, Xj2, Xj3, Xj4) for the simulated value Aj, call it CPj. For example, for the outcome vector SSSS, we have
